YBGJ (Yubo International Biotech) EBIT: $-1.13 Mil (TTM As of Mar. 2026)

What is Yubo International Biotech EBIT?

Yubo International Biotech YBGJ +30.43% EBIT is $-1.13 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Yubo International Biotech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.13 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Yubo International Biotech's annualized ROC % for the quarter that ended in Mar. 2026 was -178.40%. Yubo International Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,291.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Yubo International Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -72.09%.

Yubo International Biotech (OTCPK:YBGJ) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Yubo International Biotech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-1.156 * ( 1 - 0% )	/	( (0.698	+	0.598)	/ 2 )
=	-1.156	/	0.648
=	-178.40 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.847	-	2.272	-	( 0.008	-	max(0, 2.791	-	0.668	+	0.008	))
=	0.698

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.71	-	2.533	-	( 0.01	-	max(0, 3.019	-	0.598	+	0.01	))
=	0.598

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Yubo International Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.156	/	( ( (0.122 + max(-2.34, 0))	+	(0.057 + max(-2.685, 0)) )	/	2 )
=	-1.156	/	( ( 0.122	+	0.057 )	/	2 )
=	-1.156	/	0.0895
=	-1,291.62 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.138	+	0.024	+	0.21)	-	(2.272	+	0.44	+	0)
=	-2.34

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.134	+	0.024	+	0.137)	-	(2.533	+	0.447	+	0)
=	-2.685

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Yubo International Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-1.134	/	1.573
	=	-72.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech EBIT Related Terms

Yubo International Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's EBIT can be seen below:

Yubo International Biotech EBIT Chart

Yubo International Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-1.54

-1.21

-1.20

-1.77

-1.19

Yubo International Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-0.47	-0.25	-0.31	-0.29	-0.29

YBGJ vs ECIA, GCTK, RSCF: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yubo International Biotech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's EV-to-EBIT falls into.

Save Embed

Yubo International Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-1.13 Mil mean?

Yubo International Biotech (YBGJ) has a EBIT of $-1.13 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Yubo International Biotech.

Is Yubo International Biotech's EBIT too high?

Yubo International Biotech's current EBIT is $-1.13 Mil.

How does Yubo International Biotech's EBIT compare to ECIA and GCTK?

Yubo International Biotech's EBIT of $-1.13 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Yubo International Biotech. Yubo International Biotech's current EBIT is $-1.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Yubo International Biotech stock overvalued right now?

Yubo International Biotech (YBGJ) has a current EBIT of $-1.13 Mil. The current EBIT is $-1.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current EBIT is $-1.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ECIA GCTK RSCF CBSC NXGL CUPR LUCY ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM XSWX:STMN XTER:SRT OCSE:COLO B

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026

Website http://www.yubogroup.com

Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.